Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Ligand Pharmaceuticals (LGND) shares in India
Learn how to easily invest in Ligand Pharmaceuticals shares.
Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business based in the US. It opened the day at USD$135.85 after a previous close of USD$135.93. During the day the price has varied from a low of USD$133.13 to a high of USD$135.85. The latest price was USD$133.25 (25 minute delay). Ligand Pharmaceuticals is listed on the NASDAQ and employs 155 staff. All prices are listed in US Dollars.
Compare online trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
What's in this guide?
- Ligand Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Ligand Pharmaceuticals stock a buy or sell?
- Ligand Pharmaceuticals performance over time
- Are Ligand Pharmaceuticals shares over-valued?
- Ligand Pharmaceuticals's financials
- How volatile are Ligand Pharmaceuticals shares?
- Does Ligand Pharmaceuticals pay a dividend?
- Have Ligand Pharmaceuticals shares ever split?
- Other common questions
How has Coronavirus impacted Ligand Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Ligand Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $124.91, which is 19.36% up on its pre-crash value of $100.73 and 118.22% up on the lowest point reached during the March crash when the stocks fell as low as $57.24.
If you had bought $1,000 worth of Ligand Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $787.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,395.24.
Is it a good time to buy Ligand Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Ligand Pharmaceuticals shares at a glance
|52-week range||$102.01 - $219.75|
|50-day moving average||$152.27|
|200-day moving average||$135.27|
|Wall St. target price||$211.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$4.05|
Ligand Pharmaceuticals stock price (NASDAQ:LGND)Use our graph to track the performance of LGND stocks over time.
Ligand Pharmaceuticals price performance over time
|1 week (2022-01-07)||N/A|
|1 month (2021-12-16)||-4.67%|
|3 months (2021-10-14)||N/A|
|6 months (2021-07-16)||17.73%|
|1 year (2021-01-15)||8.03%|
|2 years (2020-01-17)||47.42%|
|3 years (2019-01-18)||13.02%|
|5 years (2017-01-18)||30.60%|
Is Ligand Pharmaceuticals under- or over-valued?
Valuing Ligand Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals's P/E ratio
Ligand Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Ligand Pharmaceuticals shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ligand Pharmaceuticals's PEG ratio
Ligand Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9687. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals's EBITDA
Ligand Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $94.2 million.
The EBITDA is a measure of a Ligand Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Ligand Pharmaceuticals financials
|Revenue TTM||$274.6 million|
|Operating margin TTM||15.79%|
|Gross profit TTM||$96.6 million|
|Return on assets TTM||2.15%|
|Return on equity TTM||9.05%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
Ligand Pharmaceuticals share dividends
We're not expecting Ligand Pharmaceuticals to pay a dividend over the next 12 months.
Have Ligand Pharmaceuticals's shares ever split?
Ligand Pharmaceuticals's shares were split on a 1:6 basis on 18 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals shares which in turn could have impacted Ligand Pharmaceuticals's share price.
Ligand Pharmaceuticals share price volatility
Over the last 12 months, Ligand Pharmaceuticals's shares have ranged in value from as little as $102.01 up to $219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals's is 1.0061. This would suggest that Ligand Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in Emeryville, California. .
Frequently asked questions
Ligand Pharmaceuticals in the news
LIGAND PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (form 8-K)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Ligand Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for LGND
More guides on Finder
How to invest in gold ETFs in India
Find out about gold ETFs, what influences their prices, how you can trade them and whether they could be worth your weight in gold.
Best Shiba Inu (SHIB) wallets
Shiba Inu (SHIB) is an ERC20 token that can be stored in any Ethereum wallet. Pick a SHIB wallet for long-term storage, short-term trading, or both.
Dogecoin vs Shiba Inu
We dive into the two most prominent meme coins to understand their similarities and differences, and to compare them on supply and other features.
How to invest in oil in India
Learn about the four options available to buy and sell this slippery commodity — as well as pros and cons.
Bitcoin ETFs guide
Bitcoin ETFs sound simple, but come in many different forms. We unpack how they work, what makes them different and compare exchanges that let you trade them.
How to buy XBTF ETF (N/A) shares in India
Steps to owning and managing N/A, with 24-hour and historical pricing before you buy.
How to buy BITO ETF units | $27.17
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re in India.
Ask an Expert